“…• TYROBP, TREM2, and complement cascade genes (C1QA, C1QB, C3) contribute to the human disease signature and are significantly increased in TASTPM heterozygous and homozygous mice Akiyama et al, 2000;Cribbs et al, 2012;Schafer et al, 2012;Zhang et al, 2013;Holtman et al, 2015;Matarin et al, 2015;Hong and Stevens, 2016;Keren-Shaul et al, 2017;Gratuze et al, 2018;Salih et al, 2019;Bartels et al, 2020 TAM family receptor agonists (Protein S and Galectin-3) associate with disease Pierce and Keating, 2014;Savage et al, 2015;Wang et al, 2015;Fourgeaud et al, 2016;Keren-Shaul et al, 2017;Krasemann et al, 2017;Mathys et al, 2017;Butovsky and Weiner, 2018;Boza-Serrano et al, 2019;Herrera-Rivero et al, 2019;Kim et al, 2019;Puigdellívol et al, 2020;Tao et al, 2020;Burstyn-Cohen and Hochberg, 2021;Huang et al, 2021 the TASTPM mouse model could be suitable as a preclinical model targeting associated microglial pathways. We suggest that TransComp-R could be useful for rational selection of mouse models in this way -the TransComp-R case study workflow we present in this study could be expanded to multiple AD mouse models.…”